Previsión
El precio objetivo medio de los analistas es de 62,55 € (+85,06 %). La mediana es de 61,06 € (+80,65 %).
| Comprar |
21 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Xenon prepares NDA submission for Azetukalner, plans specialized sales team
Xenon said at the Wells Fargo Healthcare Conference that it plans to file the New Drug Application (NDA) for Azetukalner later this month and expects all four doses (10, 15, 20, 25 mg) to be included in the prescribing information. The company intends a premium pricing strategy with a single price across all strengths and is building a commercial team of about 150 employees, including a field force of roughly 75, to reduce market access barriers. Xenon emphasized the novel Kv7 mechanism of action but anticipates a slow, stepwise launch pattern for epilepsy products; global approval plans will be supported by the ongoing Phase III X‑TOLE3 study. In parallel, Xenon is advancing programs in depression (X‑NOVA) and NaV1.7 pain, and aims to have a fully integrated commercial biopharma structure by the end of 2027. » Más en de.investing.com
Xenon Pharmaceuticals presents phase‑3 and long‑term data on epilepsy drug Azetukalner at epilepsy congress
Xenon Pharmaceuticals will present six Azetukalner presentations at the 16th European Epilepsy Congress (5–9 September 2026, Athens), including an oral presentation of the phase‑3 X-TOLE2 study in focal onset seizures. The data include results from the randomized, double‑blind, placebo‑controlled X-TOLE2 (380 participants; Azetukalner 25 mg or 15 mg vs. placebo) and findings from patients with at least 48 months of participation in the open‑label extension. In addition, mechanistic posters will show data on possible additive effects in combination with common antiseizure medications and in‑vivo evidence; Azetukalner is a potassium channel opener in development for epilepsy, major depressive disorder and bipolar depression. » Más en de.investing.com
Xenon Pharmaceuticals stock hits all-time high of $63.96
Xenon Pharmaceuticals’ share rose to a record high of $63.96, marking a yearly increase of 102.36% and a YTD gain of 35%, with market capitalization around $6.2 billion. Analysts still see strong buy consensus and maintain a high price target of $100; the stock trades near its fair value. Q1 2026 results painted a mixed picture: EPS of -$1.17 slightly beat estimates, while no revenue was reported, missing expectations. » Más en de.investing.com
Xenon Pharmaceuticals presents phase‑3 and long‑term data on azetukalner at AAN congress
Xenon Pharmaceuticals will present five abstracts at the American Academy of Neurology annual meeting, including results from the phase‑3 X‑TOLE2 study of azetukalner in focal seizures in a late‑breaking oral session and a poster session. The company will also present 48‑month interim analyses from the open‑label extension study X‑TOLE and real‑world data on titration burden and quality of life. In addition, Xenon will show preclinical data on its NaV1.1 program; azetukalner is described as a potassium channel opener being evaluated in phase‑3 studies for epilepsy and depressive disorders. » Más en de.investing.com
Driehaus boosts stake in Xenon Pharmaceuticals after Phase 3 breakthrough
Driehaus Capital Management bought 369,577 shares of Xenon Pharmaceuticals in Q4, a $15.5 million trade that raised its position to about $203.4 million (1.4% of AUM). Xenon reported strong Phase 3 results for azetukalner in focal onset seizures and plans a U.S. regulatory filing later this year. The company also completed a $747.5 million public offering, shares jumped over 30% in days and are up about 66% over the past year. » Más en finance.yahoo.com
Datos financieros
En el último trimestre, Xenon Pharmaceuticals tuvo unos ingresos de 0 € y un beneficio neto de -97,5 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | 100,00 % |
| Beneficio neto | -97,5 M | 25,88 % |
| EBITDA | -95,37 M | 24,95 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 3317,74 M € |
Número de acciones | 98,28 M |
Máximo/mínimo de 52 semanas | 66,22 € - 30,42 € |
| Dividendos | No |
Beta | 0,60 |
Ratio P/E | -7,88 |
Ratio PEG | 0,42 |
Ratio P/B | 3,22 |
Ratio P/S | 0,00 |
Perfil de la empresa
Xenon Pharmaceuticals Inc., una empresa biofarmacéutica en fase clínica, se dedica al desarrollo de terapias para tratar a pacientes con trastornos neurológicos en Canadá. Su cartera de desarrollo clínico incluye XEN496, un activador de los canales de potasio Kv7 que se encuentra en ensayos clínicos de fase III para el tratamiento de la encefalopatía epiléptica y del desarrollo asociada a KCNQ2; y XEN1101, un activador de los canales de potasio Kv7, que se encuentra en ensayo clínico de fase II para el tratamiento de la epilepsia y otros trastornos neurológicos. Los candidatos a producto de la compañía también comprenden NBI-921352, un inhibidor selectivo del canal de sodio Nav1.6 que se encuentra en ensayos clínicos de fase II para el tratamiento de la encefalopatía epiléptica y del desarrollo asociada a SCN8A, así como otras indicaciones potenciales, incluida la epilepsia focal en adultos; y XEN007, un modulador de canales de calcio de acción en el sistema nervioso central, que se encuentra en ensayos clínicos de fase II. La empresa tiene un acuerdo de licencia y colaboración con Neurocrine Biosciences, Inc. para desarrollar tratamientos para la epilepsia, y con Flexion Therapeutics, Inc. para desarrollar PCRX301 (XEN402, un inhibidor de Nav1.7) para el tratamiento del dolor postoperatorio. Xenon Pharmaceuticals Inc. fue constituida en 1996 y tiene su sede en Burnaby, Canadá.
| Nombre | Xenon Pharmaceuticals |
| CEO | Ian C. Mortimer |
| Sede | Burnaby,
bc Canadá |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 05/11/2014 |
| Empleados | 364 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | XENE |
Frankfurt | XP0.F |
Düsseldorf | XP0.DU |
München | XP0.MU |